Data gathered: April 21
AI Stock Analysis - Crispr Therapeutics (CRSP)
Analysis generated February 22, 2025. Powered by Chat GPT.
Crispr Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases. Based on CRISPR/Cas9 technology, the company pioneers next-generation gene-editing platforms aimed at curing genetic disorders. The wide application of CRISPR technology in healthcare can revolutionize how diseases are treated, making Crispr Therapeutics a potential game changer in the biotech industry.
Stock Alerts - Crispr Therapeutics (CRSP)
 |
Crispr Therapeutics | April 17 Over the past few months, there has been an upward trend in Web Traffic. |
|
Crispr Therapeutics | April 11 Price is up by 8.9% in the last 24h. |
|
Crispr Therapeutics | April 10 Price is down by -5.2% in the last 24h. |
|
Crispr Therapeutics | April 9 Price is up by 5.8% in the last 24h. |
Alternative Data for Crispr Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 1 | Sign up | Sign up | Sign up |
| Sentiment | 85 | Sign up | Sign up | Sign up |
| Webpage traffic | 211,000 | Sign up | Sign up | Sign up |
| Employee Rating | 64 | Sign up | Sign up | Sign up |
| Google Trends | 39 | Sign up | Sign up | Sign up |
| Patents | 194 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 23 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 39,351 | Sign up | Sign up | Sign up |
| Twitter Followers | 22,464 | Sign up | Sign up | Sign up |
| Twitter Mentions | 19 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | 43 | Sign up | Sign up | Sign up |
| Business Outlook | 40 | Sign up | Sign up | Sign up |
| Linkedin Employees | 420 | Sign up | Sign up | Sign up |
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA.
| Price | $38.45 |
| Target Price | Sign up |
| Volume | 680,870 |
| Market Cap | $3.26B |
| Year Range | $31.27 - $55.15 |
| Dividend Yield | 0% |
| Analyst Rating | 50% buy |
| Industry | Biotechnology |
In the news
 |
Leerink Partnrs Issues Negative Forecast for CRSP EarningsApril 18 - ETF Daily News |
|
Wells Fargo & Company MN Buys 17,094 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)April 18 - ETF Daily News |
|
Geode Capital Management LLC Sells 7,346 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)April 16 - ETF Daily News |
 |
CRISPR Therapeutics’ (CRSP) “Buy” Rating Reiterated at Needham & Company LLCApril 11 - ETF Daily News |
CRISPR Therapeutics AG (CRSP) Annual Needham Virtual Healthcare Conference (Transcript)April 8 - SeekingAlpha |
|
|
Norges Bank Makes New $17.46 Million Investment in CRISPR Therapeutics AG (NASDAQ:CRSP)April 8 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '24 | 35M | 0 | 35M | -37M | -60M | -0.440 |
| Q3 '24 | 600,000 | 11M | -11M | -86M | -105M | -1.010 |
| Q2 '24 | 520,000 | 57M | -56M | -126M | -146M | -1.490 |
| Q1 '24 | 500,000 | 52M | -51M | -117M | -136M | -1.430 |
| Q4 '23 | 200M | 20M | 180M | 89M | 74M | 1.100 |
Insider Transactions View All
| KASINGER JAMES R. filed to sell 81,729 shares at $41.2. March 24 '25 |
| Prasad Raju filed to sell 16,767 shares at $41.2. March 24 '25 |
| Bruno Julianne filed to sell 10,544 shares at $41.2. March 24 '25 |
| Kulkarni Samarth filed to sell 195,085 shares at $41.2. March 24 '25 |
| Prasad Raju filed to sell 12,714 shares at $41.8. March 18 '25 |
Similar companies
Read more about Crispr Therapeutics (CRSP) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Crispr Therapeutics?
The Market Cap of Crispr Therapeutics is $3.26B.
What is the current stock price of Crispr Therapeutics?
Currently, the price of one share of Crispr Therapeutics stock is $38.45.
How can I analyze the CRSP stock price chart for investment decisions?
The CRSP stock price chart above provides a comprehensive visual representation of Crispr Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Crispr Therapeutics shares. Our platform offers an up-to-date CRSP stock price chart, along with technical data analysis and alternative data insights.
Does CRSP offer dividends to its shareholders?
As of our latest update, Crispr Therapeutics (CRSP) does not offer dividends to its shareholders. Investors interested in Crispr Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Crispr Therapeutics?
Some of the similar stocks of Crispr Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.